Trial · NCT06881888
Intranasal Delivery of Octreotide for Treatment of Diabetic Macular Edema
NCT06881888, Phase 1, Withdrawn, University of Alabama at Birmingham
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Intranasal Delivery of Octreotide for Treatment of Diabetic Macular Edema. Trials, record NCT06881888. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT06881888
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Intranasal Delivery of Octreotide for Treatment of Diabetic Macular Edema
- NCT number
- NCT06881888
- Status
- Withdrawn
- Phases
- Phase 1
- Enrollment
- 0 participants, actual
- Lead sponsor
- University of Alabama at Birmingham
- Conditions
- Diabetic Macular Edema
- Interventions
- Octreotide (drug), Placebo
- First posted
- 2025-03-18
- Last updated
- 2026-10-13
Source ClinicalTrials.gov
Registered outcomes8
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Change in macular central subfield thickness | Up to one month. | Participants will have an optical coherence tomography at each visit that will measure macular central subfield thickness. Measuring the change at their baseline appointment and each additional study visit. |
| Primary | Change in best corrected visual acuity | Up to one month. | Each participant will have best corrected visual acuity measured by Early Treatment of Diabetic Retinopathy study (ETDRS) chart. Enter the full scale. |
| Primary | Change in microglia on retinal surface | Up to one month | Each participant will have an optical coherence tomography angiography scan measuring the quantity of microglia on the retinal surface. |
| Primary | Changes in retinal peripheral capillary free zone | up to one month | Each participant will have optical coherence tomography angiography and measure differences in retinal peripheral capillary free zone. |
| Primary | Changes in retinal foveal avascular zone | up to one month | Each participant will have optical coherence tomography angiography and measure differences in retinal foveal avascular zone. |
| Primary | Changes in retinal capillary density | up to one month | Each participant will have optical coherence tomography angiography and measure differences in retinal capillary density. |
| Primary | Changes in retinal non-perfusion zones | up to one month | Each participant will have optical coherence tomography angiography and measure differences in retinal non-perfusion zones. |
| Secondary | Changes in serum insulin like growth factor -1 (IGF-1) levels | up to one month. | Each participant will have serum IGF-1 levels measured. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT06881888
GET https://conductscience.org/api/trials/v1/NCT06881888/registered